Economic aspects and evidence-based decision making in evaluating patients with suspected small bowel disorders

Obscure gastrointestinal hemorrhage is defined as overt or occult bleeding present after normal endoscopic examination of the upper and lower gastrointestinal tracts. Approximately 5% of patients with gastrointestinal hemorrhage can be classified as having obscure bleeding, with most patients found to have responsible lesions in the small intestine. The advent of video capsule endoscopy and deep enteroscopy allows for endoscopic access and therapeutic options in the small intestine. In our current era of cost minimization, reductions in capital equipment expenditures, and a high rate of malpractice claims against clinicians, the decision regarding whether a clinical enterprise should offer small bowel endoscopy using any of the more recent technologies requires an understanding of several factors. This article highlights some of the economic and medicolegal aspects of deep small bowel endoscopy. The following topics will be discussed: costs involved to perform endoscopic imaging of the small bowel; downstream revenue effect resulting from deep enteroscopy; coding, billing, and reimbursement issues; cost-effectiveness studies for diagnostic testing; algorithms for diagnostic evaluation of patients with suspected small bowel pathology; and medicolegal ramifications associated with endoscopic procedures of the small bowel.